Repositorio Dspace

Targeting the epigenetics of the DNA damage response in breast cancer

Mostrar el registro sencillo del ítem

dc.contributor.author Montenegro, María-Fernanda
dc.contributor.author González-Guerrero, R
dc.contributor.author Rodríguez-López, JN
dc.contributor.author Sánchez-del-Campo, L
dc.contributor.author Piñero-Madrona, Antonio
dc.contributor.author Cabezas-Herrera, Juan
dc.date.accessioned 2026-10-21T06:19:58Z
dc.date.available 2026-10-21T06:19:58Z
dc.date.issued 2016-04-07
dc.identifier.citation Montenegro MF, González-Guerrero R, Sánchez-del-Campo L, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN. Targeting the epigenetics of the DNA damage response in breast cancer. Cell Death Dis. 7 de abril de 2016;7(4):e2180-e2180. doi:10.1038/cddis.2016.85
dc.identifier.issn 2041-4889
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28887
dc.description.abstract Cancer is as much an epigenetic disease as it is a genetic disease, and epigenetic alterations in cancer often serve as potent surrogates for genetic mutations. Because the epigenetic factors involved in the DNA damage response are regulated by multiple elements, therapies to target specific components of the epigenetic machinery can be inefficient. In contrast, therapies aimed at inhibiting the methionine cycle can indirectly inhibit both DNA and protein methylation, and the wide variety of genes and pathways that are affected by these methylations make this global strategy very attractive. In the present study, we propose an adjuvant therapy that targets the epigenetics of the DNA damage response in breast cancer cells and that results in efficient apoptosis and a reduction in distant metastases in vivo. We observed that a combined therapy designed to uncouple adenosine metabolism using dipyridamole in the presence of a new synthetic antifolate, 3-O-(3,4,5-trimethoxybenzoyl)-(-)-catechin, simultaneously and efficiently blocked both the folic cycle and the methionine cycle in breast cancer cells and sensitized these cells to radiotherapy. The treatment impeded the recruitment of 53BP1 and BRCA1 to the chromatin regions flanking DNA double-strand breaks and thereby avoided the DNA damage responses in breast cancer cells that were exposed to ionizing radiation. In addition, this hypomethylating therapy was also efficient in reducing the self-renewal capability of breast cancer-initiating cells and induced reversion of mesenchymal phenotypes in breast cancer cells.
dc.language.iso eng
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Animals
dc.subject.mesh Apoptosis/drug effects/radiation effects
dc.subject.mesh BRCA1 Protein/metabolism
dc.subject.mesh Breast Neoplasms/metabolism/pathology/radiotherapy
dc.subject.mesh Cell Cycle Checkpoints/drug effects/radiation effects
dc.subject.mesh Cell Line, Tumor
dc.subject.mesh Chromatin/metabolism
dc.subject.mesh DNA Breaks, Double-Stranded/drug effects/radiation effects
dc.subject.mesh DNA Repair/drug effects/radiation effects
dc.subject.mesh Dipyridamole/metabolism
dc.subject.mesh Epigenesis, Genetic
dc.subject.mesh Female
dc.subject.mesh Folic Acid Antagonists/pharmacology
dc.subject.mesh Histones/metabolism
dc.subject.mesh Humans
dc.subject.mesh MCF-7 Cells
dc.subject.mesh Methylation/drug effects/radiation effects
dc.subject.mesh Mice
dc.subject.mesh Mice, Inbred BALB C
dc.subject.mesh Protein-Arginine N-Methyltransferases/antagonists & inhibitors/genetics/metabolism
dc.subject.mesh Repressor Proteins/antagonists & inhibitors/genetics/metabolism
dc.subject.mesh Tumor Suppressor p53-Binding Protein 1/metabolism
dc.title Targeting the epigenetics of the DNA damage response in breast cancer
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 27054335
dc.relation.publisherversion https://www.nature.com/articles/cddis201685
dc.identifier.doi 10.1038/cddis.2016.85
dc.journal.title Cell Death & Disease


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta